DE602004027409D1 - Tetrahydrofuroä3,4-düdioxolverbindungen und zusammensetzungen und verfahren zur inhibierung der trombozytenaggregation - Google Patents

Tetrahydrofuroä3,4-düdioxolverbindungen und zusammensetzungen und verfahren zur inhibierung der trombozytenaggregation

Info

Publication number
DE602004027409D1
DE602004027409D1 DE602004027409T DE602004027409T DE602004027409D1 DE 602004027409 D1 DE602004027409 D1 DE 602004027409D1 DE 602004027409 T DE602004027409 T DE 602004027409T DE 602004027409 T DE602004027409 T DE 602004027409T DE 602004027409 D1 DE602004027409 D1 DE 602004027409D1
Authority
DE
Germany
Prior art keywords
compounds
aggregation
trombozyte
dedioxol
tetrahydrofuro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602004027409T
Other languages
English (en)
Inventor
Robert Plourde Jr
Sammy Ray Shaver
Melwyn Anthony Abreo
Lorenzo Josue Alfaro-Lopez
Yangbo Feng
Daniel F Harvey
Tatyana V Khasanova
Chi Tu
Jose L Boyer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Inspire Pharmaceuticals Inc
Original Assignee
Inspire Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inspire Pharmaceuticals Inc filed Critical Inspire Pharmaceuticals Inc
Publication of DE602004027409D1 publication Critical patent/DE602004027409D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
DE602004027409T 2003-10-21 2004-10-21 Tetrahydrofuroä3,4-düdioxolverbindungen und zusammensetzungen und verfahren zur inhibierung der trombozytenaggregation Active DE602004027409D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51384503P 2003-10-21 2003-10-21
PCT/US2004/035389 WO2005040174A1 (en) 2003-10-21 2004-10-21 Tetrahydro-furo`3,4-d!dioxole compounds and compositions and method for inhibiting platelet aggregation

Publications (1)

Publication Number Publication Date
DE602004027409D1 true DE602004027409D1 (de) 2010-07-08

Family

ID=34520144

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004027409T Active DE602004027409D1 (de) 2003-10-21 2004-10-21 Tetrahydrofuroä3,4-düdioxolverbindungen und zusammensetzungen und verfahren zur inhibierung der trombozytenaggregation

Country Status (7)

Country Link
US (1) US7368438B2 (de)
EP (1) EP1685135B1 (de)
JP (1) JP2007514647A (de)
AT (1) ATE469157T1 (de)
AU (2) AU2004284098B2 (de)
DE (1) DE602004027409D1 (de)
WO (1) WO2005040174A1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7452870B2 (en) 2000-08-21 2008-11-18 Inspire Pharmaceuticals, Inc. Drug-eluting stents coated with P2Y12 receptor antagonist compound
US7504497B2 (en) 2003-10-21 2009-03-17 Inspire Pharmaceuticals, Inc. Orally bioavailable compounds and methods for inhibiting platelet aggregation
US7335648B2 (en) * 2003-10-21 2008-02-26 Inspire Pharmaceuticals, Inc. Non-nucleotide composition and method for inhibiting platelet aggregation
US7749981B2 (en) * 2003-10-21 2010-07-06 Inspire Pharmaceuticals, Inc. Drug-eluting stents coated with non-nucleotide P2Y12 receptor antagonist compound
WO2005039590A1 (en) * 2003-10-21 2005-05-06 Inspire Pharmaceuticals, Inc. Non-nucleotide compositions and method for treating pain
WO2006105529A1 (en) * 2005-03-30 2006-10-05 Inspire Pharmaceuticals, Inc. Process for the preparation of 4,6-disubstituted-tetrahydro-furo, thieno, pyrrolo and cyclopenta-[3,4][1,3]dioxoles
WO2007056217A2 (en) * 2005-11-04 2007-05-18 Inspire Pharmaceuticals, Inc. Drug-eluting stents coated with non-nucleotide p2y12 receptor antagonist compound
US20070249556A1 (en) * 2006-04-21 2007-10-25 Brubaker Kurt E Method of treating inflammation
CA2657973A1 (en) * 2006-06-27 2008-01-03 Biovitrum Ab (Publ) Therapeutic compounds
WO2008151024A1 (en) * 2007-05-30 2008-12-11 Brigham Young University Protein kinase-binding nucleosides and associated methods
EP2364086B1 (de) * 2008-11-20 2016-09-14 Glsynthesis Inc. Neue antithrombotische diadenosintetraphosphate und entsprechende analoga
CA2747658A1 (en) * 2008-12-18 2010-07-15 Inspire Pharmaceuticals, Inc. Method for treating inflammatory conditions
EP2408306A4 (de) * 2009-03-20 2012-11-07 Alios Biopharma Inc Substituierte nukleosid- und nukleotid-analoga
NZ607996A (en) 2010-09-22 2014-07-25 Alios Biopharma Inc Substituted nucleotide analogs
JP5768422B2 (ja) * 2011-03-17 2015-08-26 ソニー株式会社 血液凝固系解析方法および血液凝固系解析装置
EP2750676B1 (de) 2011-08-30 2018-01-10 University of Utah Research Foundation Verfahren und zusammensetzungen zur behandlung von nephrogenem diabetes insipidus
EP2794630A4 (de) 2011-12-22 2015-04-01 Alios Biopharma Inc Substituierte phosphorthioat-nukleotidanaloga
CN104321333A (zh) 2012-03-21 2015-01-28 沃泰克斯药物股份有限公司 硫代氨基磷酸酯核苷酸前药的固体形式
WO2013142157A1 (en) 2012-03-22 2013-09-26 Alios Biopharma, Inc. Pharmaceutical combinations comprising a thionucleotide analog

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3321462A (en) * 1963-07-15 1967-05-23 Syntex Corp Process for the preparation of nucleoside polyphosphates
AU8379182A (en) 1981-06-04 1982-12-09 Procter & Gamble Company, The Composition of salicylates and purine derivatives
US4794174A (en) * 1987-02-10 1988-12-27 Southern Research Institute 5'deoxy-5'-substituted adenosines
US5049550A (en) * 1987-11-05 1991-09-17 Worcester Foundation For Experimental Biology Diadenosine 5', 5'"-p1, p4,-tetraphosphate analogs as antithrombotic agents
US5292725A (en) * 1988-08-25 1994-03-08 Prendergast Patrick T Administering particular compounds against various parasites, mycoplasmas, other indications and other infections
NZ239846A (en) * 1990-09-27 1994-11-25 Merck & Co Inc Sulphonamide derivatives and pharmaceutical compositions thereof
GB9122308D0 (en) * 1991-10-21 1991-12-04 British Bio Technology Compounds
WO1996019223A1 (en) * 1994-12-22 1996-06-27 Smithkline Beecham Corporation Fibrinogen receptor antagonists
WO1997003084A1 (en) * 1995-07-11 1997-01-30 Astra Pharmaceuticals Ltd. New inhibitors of platelet aggregation
US5681823A (en) * 1996-05-02 1997-10-28 Prp Inc. P1, P4 -dithio-P2 -P3 -monochloromethylene 5', 5'"-diadenosine P1, P4 -tetraphosphate as antithrombotic agent
ATE213245T1 (de) 1996-12-20 2002-02-15 Triazolo(4,5-d)pyrimidinyl-derivate und ihre verwendung als medikamente
SE9702774D0 (sv) 1997-07-22 1997-07-22 Astra Pharma Prod Novel compounds
SE9702772D0 (sv) 1997-07-22 1997-07-22 Astra Pharma Prod Novel compounds
AR017014A1 (es) 1997-07-22 2001-08-22 Astrazeneca Ab Compuestos de triazolo [4,5-d]pirimidina, composiciones farmaceuticas, uso de los mismos para preparar medicamentos y procesos para la preparacionde dichos compuestos
EP1019427A4 (de) 1997-07-29 2000-07-19 Medco Res Inc N6-substituierte adenosin-5'-uronamide als adenosin-rezeptor-modulatoren
MXPA00007634A (es) 1998-02-17 2003-09-10 Astrazeneca Uk Ltd Nuevos compuestos de triazol (4,5-d) pirimidina.
SE9802574D0 (sv) 1998-07-17 1998-07-17 Astra Pharma Prod Novel compounds
SE9804175D0 (sv) 1998-12-02 1998-12-02 Astra Pharma Prod New assay
SE9903290D0 (sv) * 1999-09-15 1999-09-15 Astra Pharma Prod Novel compounds
SE9904128D0 (sv) 1999-11-15 1999-11-15 Astra Pharma Prod Novel compounds
US6605597B1 (en) 1999-12-03 2003-08-12 Cv Therapeutics, Inc. Partial or full A1agonists-N-6 heterocyclic 5′-thio substituted adenosine derivatives
TWI227240B (en) 2000-06-06 2005-02-01 Pfizer 2-aminocarbonyl-9H-purine derivatives
US7018985B1 (en) * 2000-08-21 2006-03-28 Inspire Pharmaceuticals, Inc. Composition and method for inhibiting platelet aggregation
SE0101932D0 (sv) 2001-05-31 2001-05-31 Astrazeneca Ab Pharmaceutical combinations
EP1348466A3 (de) 2002-02-01 2003-10-29 Inspire Pharmaceuticals, Inc. Schmerzbehandlung mit Adenosin-Tetraphosphaten
UA83648C2 (ru) * 2002-12-11 2008-08-11 Шеринг Акциенгезельшафт Антагонисты аденозиндифосфатного рецептора тромбоцитов
US7335648B2 (en) * 2003-10-21 2008-02-26 Inspire Pharmaceuticals, Inc. Non-nucleotide composition and method for inhibiting platelet aggregation

Also Published As

Publication number Publication date
US20050159388A1 (en) 2005-07-21
EP1685135A1 (de) 2006-08-02
AU2004284098B2 (en) 2009-07-16
ATE469157T1 (de) 2010-06-15
WO2005040174A1 (en) 2005-05-06
AU2009222625A1 (en) 2009-10-29
AU2004284098A1 (en) 2005-05-06
JP2007514647A (ja) 2007-06-07
EP1685135B1 (de) 2010-05-26
US7368438B2 (en) 2008-05-06

Similar Documents

Publication Publication Date Title
DE602004027409D1 (de) Tetrahydrofuroä3,4-düdioxolverbindungen und zusammensetzungen und verfahren zur inhibierung der trombozytenaggregation
WO2006119507A3 (en) Non-nucleotide composition and method for inhibiting platelet aggregation
TWI265931B (en) Composition and method for inhibiting platelet aggregation
ATE517882T1 (de) Chinolinderivate
BRPI0410630A (pt) antagonista de nk1
WO2005097814A3 (en) Composition and method for inhibiting platelet aggregation
BRPI0507495A (pt) composto, composição farmacêutica, uso do composto método para o tratamento de distúrbios mediados por mglur5, e, método para inibir a ativação de receptores de mglur5
ATE464304T1 (de) Carboxamid-spirolactam-cgrp-rezeptor-antagonist n
EA200300424A1 (ru) Соли изотиазол-4-карбоксамида и их применение в качестве антигиперпролиферативных агентов
TW200728260A (en) Substituted-(quinazolinyl)phenyl thiophenyl-sulfonylureas, methods for making and intermediates thereof
EA200500814A1 (ru) Производные пирролопиримидина
DE60324544D1 (de) Muskarin antagonisten
ATE446303T1 (de) Agonisten und antagonisten von sphingosin-1- phosphatrezeptoren
EA200901159A1 (ru) Производные 3-циано-4-(4-фенилпиперидин-1-ил)пиридин-2-она
AR036596A1 (es) Derivados de 4,5-dihidro-1h-pirazol que tienen actividad antagonista de cb1
EA200500342A1 (ru) Гетероциклические замещённые пиперазины для лечения шизофрении
MX2007012936A (es) Derivados de dihidrobenzofurano y usos de los mismos.
SE0302760D0 (sv) New compounds
ATE538784T1 (de) Verfahren zur behandlung von substanzbedingten erkrankungen
DE602005027230D1 (de) Cgrp-rezeptorantagonisten
BR0309486A (pt) Composto ou um seu sal farmaceuticamente aceitável, composição farmacêutica, e, método para o tratamento de uma condição associada com um excesso de taquicininas
BR9909597A (pt) Composto, composição farmacêutica e método de tratamento de câncer e doenças proliferativas
EA200400467A1 (ru) Производные 3-азабицикло (3.1.0) гексана в качестве антагонистов опиоидного рецептора
TW200716547A (en) Piperidin-4-yl-amide derivatives
BRPI0517032A (pt) compostos, processo para a sua manufatura, composições farmacêuticas que os compreendem, método para o tratamento e/ou prevenção de enfermidades e utilização desses compostos

Legal Events

Date Code Title Description
8364 No opposition during term of opposition